Results 141 to 150 of about 53,199 (230)

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, Volume 293, Issue 17, Page 5107-5120, September 2026.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines. [PDF]

Int J Mol Sci
Sattarifard H, Oyeyode M, Prajapati D, Duaqui A, Kaur G, Muker I, Luo W, Lakowski TM, Davie JR.   +8 more
europepmc   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, Volume 293, Issue 17, Page 5121-5139, September 2026.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting. [PDF]

Open Heart
Henriques Peck O, McCoubrey A, Snowden JA, Wechalekar A, Travers J, Lees JS, Petrie MC, Lang NN.   +7 more
europepmc   +1 more source

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review

, 2016
Wendong Chen,1 Yicheng Yang,2 Yi Chen,3 Fen Du,3 Huan Zhan3 1Normin Health, Toronto, ON, Canada; 2Xian Janssen, Beijing, People's Republic of China; 3Normin Health Changsha Representative Office, Changsha, People's Republic of China Objectives ...
Yang Y, Du F, Chen W, Zhan H, Chen Y
core  

Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Journal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‐naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‐analysis was intended to evaluate their efficacy, addressing critical gaps
Fangfei Xu, Xiuping Zou, Yulin Yang, Kuangguo Zhou, Wei Huang   +4 more
wiley   +1 more source

Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment. [PDF]

Pharmaceuticals (Basel)
Lucijanic M, Orec J, Soric E, Sabljic A, Jonjic Z, Pirsic M, Jaksic O.   +6 more
europepmc   +1 more source

An Approach to Antibody‐Mediated Rejection in Pediatric Liver Transplantation

Pediatric Transplantation, Volume 30, Issue 9, September 2026.
ABSTRACT Antibody‐mediated rejection (AMR) is an important but infrequent cause of pediatric liver allograft injury. There is a lack of standardized guidance, and treatment approaches vary across institutions. A writing group from the Society of Pediatric Liver Transplantation conducted a comprehensive review of the published literature and collected ...
Catalina Jaramillo, Parmjeet Randhawa, Amrita Narang, Alison J. Gareau, Jody Weckwerth, Alisha Mavis, George Mazariegos, Katryn Furuya, Nanda Kerkar   +8 more
wiley   +1 more source

Thermodynamic Preference Between Deprotonation Pathways in Boronic Acid-Based Proteasome Inhibitors: Insights from a DFT Study. [PDF]

Pharmaceuticals (Basel)
Toshev N, Dimitrov I, Muradyan O, Delchev V, Dudev T.   +4 more
europepmc   +1 more source

Unusual Cutaneous and Lymphatic Findings in an Adult Patient

JEADV Clinical Practice, Volume 5, Issue 3, Page 1023-1025, September 2026.
Sarah Preis, Mara Hubbuch, Susanne Annette Steimle‐Grauer, Tilo Biedermann, Oana‐Diana Persa   +4 more
wiley   +1 more source